AstraZeneca's Tagrisso (osimertinib) Receives EU's Approval for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Lung Cancer
Shots:
- The approval is based on P-III ADAURA trial assessing Tagrisso (80mg- qd- PO) vs PBO in 682 patients with stage IB- II- IIIA EGFRm NSCLC following complete tumor resection and adjuvant CT as indicated for 3 yrs. or until disease recurrence
- Results: Improvement in DFS in all primary analysis population in Stage II and IIIA EGFRm NSCLC patients and overall trial population- 83% reduction in the risk of disease recurrence or death- and 80% reduction in the overall trial population in patients with Stage IB-IIIA disease
- Tagrisso is an approved therapy for 1L LA or mEGFRm NSCLC and for LA or mEGFR T790M mutation+ NSCLC in the EU- the US- Japan- China and many other countries
Ref: AstraZeneca | Image: New Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com